Catalyst Seeks Development Partners

Catalyst is seeking partnerships for CPP-109 and CPP-115, as well as in-licensing opportunities for prescription drugs to treat central nervous system (CNS) diseases and disorders. For further information, please contact:

Richard P. Rieger,
Vice President, Commercial Operations
(305) 529-2522

Working with NIDA

Catalyst has initiated a registration-directed Phase II(b) clinical trial to evaluate CPP-109 for treatment of cocaine addiction in collaboration with the National Institute on Drug Abuse (NIDA) and the Veterans Health Admin­istration Cooperative Studies Program. More »

Catalyst announced the agreement with NIDA to collaborate on this Phase II(b) clinical trial in April 2010. More »